San Francisco, CA, United States of America

Troy Evan Reynolds

This inventor holds 6 USPTO granted patents, plus 2 CIPO patents and 3 EPO patents. Top assignee: Gilead Sciences, Inc.. Active years: 2016-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Troy Evan Reynolds. Retrieved from https://idiyas.com/inventor/troy-evan-reynolds

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

 

Average Co-Inventor Count = 4.7

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • San Francisco, CA (US) (2016 - 2020)
  • Winnetka, IL (US) (2022)

Company Filing History:


Years Active: 2016-2022

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Troy Evan Reynolds

Introduction

Troy Evan Reynolds is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of ASK1 inhibitors. With a total of 6 patents to his name, Reynolds has established himself as a key figure in medical research and innovation.

Latest Patents

Reynolds' latest patents focus on processes for preparing ASK1 inhibitors. These compounds exhibit apoptosis signal-regulating kinase ('ASK1') inhibitory activity, making them useful in treating various diseases, including kidney disease, diabetic nephropathy, and kidney fibrosis. The patents also detail synthetic intermediates that are crucial for the preparation of these compounds.

Career Highlights

Reynolds is currently employed at Gilead Sciences, Inc., where he continues to advance his research in the pharmaceutical industry. His work has been instrumental in developing new therapeutic options for patients suffering from serious health conditions.

Collaborations

Throughout his career, Reynolds has collaborated with notable colleagues, including Brandon Heath Brown and Ernest A Carra. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Troy Evan Reynolds is a dedicated inventor whose work in developing ASK1 inhibitors has the potential to impact the treatment of critical diseases. His contributions to the field of pharmaceuticals underscore the importance of innovation in improving healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…